Previous Close | 7.445 |
1-Year Change | 23.88% |
6-Months Change | 63.63% |
3-Months Change | 18.55% |
Moving Avg (50d) | 6.0661 |
Moving Avg (200d) | 5.226 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 0.606B |
Beta (3-Years) | 1.9 |
Revenue Growth (ttm) | % |
Net Profit Margin (ttm) | 50.65% |
Return On Assets (ttm) | -32.73% |
EPS (ttm) | -0.65 |
PE Ratio (ttm) | -11.45 |
Dividend Yield | % |
Asset Description: | Anavex Life Sciences Corp. |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-11-19 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
8.84 | 8.569 | 8.389 | 8.118 | 7.667 | 7.216 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |